Understanding the TME has significant implications for cancer therapy. Targeting the TME components can enhance the efficacy of existing treatments and lead to the development of novel therapeutic strategies:
- Anti-Angiogenic Therapy: Drugs targeting angiogenesis, such as bevacizumab, aim to disrupt the blood supply to the tumor. - Immune Checkpoint Inhibitors: These therapies, including drugs like pembrolizumab and nivolumab, aim to restore anti-tumor immunity by blocking inhibitory signals in the TME. - Stromal Targeting: Strategies to modify the ECM or inhibit the activity of CAFs can potentially hinder tumor progression and metastasis.
